About Krebs Biochemicals and Industries Limited
Data last updated:
Krebs Biochemicals and Industries Limited is a public limited company based in Anakapalli, Telangana, India. It operates in the biotechnology segment of the life sciences sector. It was incorporated on 02 December 1991 and has been in existence for over 35 years.
The company is registered with the Registrar of Companies (ROC), Vijayawada, under CIN L24110AP1991PLC103912. Its GSTIN is 37AAACK8355M1Z0 (Andhra Pradesh). The company holds 3 GST registrations, of which 2 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 524518 and NSE: KREBSBIO.
The company has an authorised share capital of ₹153 Cr and a paid-up capital of ₹151.56 Cr. It was formerly known as Krebs Biochemicals Limited. It is led by directors including Manish Kumar Jain (Managing Director) and Avinash Ravi.
Its last annual general meeting (AGM) was held on 26 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Kothapalli Village Kasimkota Mandal, Anakapalli, Telangana, India – 531031.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹23.73 Cr, a decline of 45.2% compared to the previous year. For the same year it recorded a net loss of ₹16.93 Cr (net margin -71.3%) and EBITDA of -₹5.45 Cr (EBITDA margin -23%). Total assets are valued at ₹111.47 Cr (down 4.3% YoY).
The company has about 335 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Krebs Biochemicals. As per MCA filings, the company has open charges of ₹14.35 Cr and satisfied charges of ₹285.88 Cr on record. Court records list 114 cases involving the company, including 56 filed by the company and 58 filed against it; 15 cases are pending. The company has 14 deals on record (9 market trades, 2 acquisitions, 2 funding rounds), with disclosed funding of ₹200 Cr; the latest was in November 2024. The company has 32 MSME Form 1 returns on record between 2009 and 2024, listing 3,550 overdue payments to 87 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website krebsbiochem.com.
Company details
CIN history
Krebs Biochemicals and Industries has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24110AP1991PLC103912, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24110AP1991PLC103912 | Current |
| L24110AP1991PLC013511 | Previous |
| L24110TG1991PLC013511 | Previous |
Contact details
Krebs Biochemicals and Industries Limited's registered office is in Anakapalli, Telangana. Its website is krebsbiochem.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressKothapalli Village Kasimkota Mandal, Anakapalli, Telangana, India – 531031
- IndustryLife Sciences, Biotechnology
To see the full contact details of Krebs Biochemicals and Industries Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Krebs Biochemicals and Industries operates one associated brand: Krebs Biochemicals. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Biotech processes are developed for medicine and agriculture uses. | krebsbiochem.com |
Business activity
The main business activity of Krebs Biochemicals and Industries is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Krebs Biochemicals and Industries Limited, buy the company report.
Financials of Krebs Biochemicals and Industries Limited
FY 2025-26 filings availableKrebs Biochemicals and Industries Limited reported revenue of ₹23.73 Cr (down 45.2% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 23.73 | 43.31 | 50.42 | 52.13 | 59.70 | 53.70 | 33.41 |
| Revenue growth | -45.2% | -14.1% | -3.3% | -12.7% | +11.2% | +60.7% | - |
| EBITDA | (5.45) | (15.03) | (8.71) | (15.80) | (33.99) | (17.56) | (18.56) |
| EBITDA margin | -23.0% | -34.7% | -17.3% | -30.3% | -56.9% | -32.7% | -55.6% |
| Profit before tax | (16.93) | (26.92) | (19.72) | (24.71) | (44.52) | (28.34) | (28.87) |
| Net profit | (16.93) | (27.06) | (19.72) | (24.71) | (44.52) | (28.34) | (28.88) |
| Net profit margin | -71.3% | -62.5% | -39.1% | -47.4% | -74.6% | -52.8% | -86.4% |
| EPS (₹) | (7.85) | (12.49) | (9.15) | (11.45) | (20.65) | (14.45) | (16.04) |
| Balance sheet | |||||||
| Total assets | 111 | 116 | 127 | 136 | 122 | 122 | 91.37 |
| Net worth | (32.76) | (16.24) | 10.78 | 30.54 | 54.91 | (12.73) | 5.00 |
| Total debt | 94.84 | 82.21 | 63.68 | 53.37 | 13.10 | 81.14 | 36.22 |
| Cash & bank | 0.13 | 0.14 | 0.14 | 0.09 | 0.10 | 0.71 | 0.17 |
| Net working capital | (42.16) | (42.31) | (34.21) | (22.91) | (32.41) | (16.18) | (23.57) |
| Cash flow | |||||||
| Cash from operations | (1.92) | (7.89) | 2.36 | (24.71) | (17.22) | (14.57) | (35.50) |
| Cash from investing | (3.64) | (4.97) | (7.82) | (12.65) | (22.90) | (22.55) | (10.22) |
| Cash from financing | 5.54 | 12.86 | 5.50 | 37.34 | 39.51 | 37.66 | 28.58 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5.79 | 6.98 | 6.81 | 7.27 | 4.17 | 5.48 | 6.10 | 11.47 |
| Revenue growth (YoY) | +38.9% | +27.4% | +11.6% | -36.6% | -67.6% | -57.5% | - | - |
| Other income | 0.04 | 0.16 | 2.00 | 0.00 | 0.01 | 0.01 | 0.34 | 0.25 |
| Total expenses | 7.72 | 6.16 | 7.68 | 6.98 | 6.96 | 7.57 | 11.51 | 16.18 |
| EBITDA | (1.93) | 0.82 | (0.87) | 0.29 | (2.79) | (2.09) | (5.41) | (4.71) |
| EBITDA margin | -33.3% | +11.7% | -12.8% | +4.0% | -66.9% | -38.1% | -88.7% | -41.1% |
| Depreciation | 1.61 | 1.59 | 1.57 | 1.63 | 1.62 | 1.60 | 1.57 | 1.72 |
| Interest | 1.90 | 1.88 | 1.91 | 1.79 | 1.73 | 1.65 | 1.61 | 1.56 |
| Profit before tax | (5.40) | (2.49) | (2.35) | (3.13) | (6.13) | (5.33) | (8.25) | (7.74) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5.79 | 6.98 | 6.81 | 7.27 | 4.17 | 5.48 | 6.10 | 11.47 |
| Revenue growth (YoY) | +38.9% | +27.4% | +11.6% | -36.6% | -67.6% | -57.5% | - | - |
| Other income | 0.04 | 0.16 | 2.00 | 0.00 | 0.01 | 0.01 | 0.34 | 0.25 |
| Total expenses | 7.72 | 6.16 | 7.68 | 6.98 | 6.96 | 7.57 | 11.51 | 16.18 |
| EBITDA | (1.93) | 0.82 | (0.87) | 0.29 | (2.79) | (2.09) | (5.41) | (4.71) |
| EBITDA margin | -33.3% | +11.7% | -12.8% | +4.0% | -66.9% | -38.1% | -88.7% | -41.1% |
| Depreciation | 1.61 | 1.59 | 1.57 | 1.63 | 1.62 | 1.60 | 1.57 | 1.72 |
| Interest | 1.90 | 1.88 | 1.91 | 1.79 | 1.73 | 1.65 | 1.61 | 1.56 |
| Profit before tax | (5.40) | (2.49) | (2.35) | (3.13) | (6.13) | (5.33) | (8.25) | (7.74) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 23.73 | 43.31 | 50.42 | 52.13 | 59.70 | 53.70 | 33.41 |
| Revenue growth | -45.2% | -14.1% | -3.3% | -12.7% | +11.2% | +60.7% | - |
| Other income | 2.03 | 0.71 | 0.45 | 0.62 | 1.16 | 0.62 | 0.37 |
| Total expenses | 29.18 | 58.34 | 59.13 | 67.93 | 93.69 | 71.26 | 51.97 |
| Employee cost | 0.00 | 16.30 | 16.17 | 15.54 | 14.96 | 15.30 | 14.56 |
| EBITDA | (5.45) | (15.03) | (8.71) | (15.80) | (33.99) | (17.56) | (18.56) |
| EBITDA margin | -23.0% | -34.7% | -17.3% | -30.3% | -56.9% | -32.7% | -55.6% |
| Depreciation | 6.42 | 6.69 | 6.77 | 6.56 | 6.30 | 5.12 | 4.68 |
| Interest | 7.09 | 5.91 | 4.69 | 2.97 | 5.39 | 6.28 | 6.00 |
| Profit before tax | (16.93) | (26.92) | (19.72) | (24.71) | (44.52) | (28.34) | (28.87) |
| Tax | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net profit | (16.93) | (27.06) | (19.72) | (24.71) | (44.52) | (28.34) | (28.88) |
| Net profit margin | -71.3% | -62.5% | -39.1% | -47.4% | -74.6% | -52.8% | -86.4% |
| EPS (₹) | (7.85) | (12.49) | (9.15) | (11.45) | (20.65) | (14.45) | (16.04) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 152 | 152 | 152 | 152 | 152 | 49.62 | 48.00 |
| Reserves & surplus | (184) | (168) | (141) | (121) | (96.65) | (66.52) | (43.00) |
| Shareholders' funds (net worth) | (32.76) | (16.24) | 10.78 | 30.54 | 54.91 | (12.73) | 5.00 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 71.14 | 35.51 |
| Unsecured loans | 94.84 | 82.21 | 63.68 | 53.37 | 13.10 | 10.00 | 0.71 |
| Total debt | 94.84 | 82.21 | 63.68 | 53.37 | 13.10 | 81.14 | 36.22 |
| Total liabilities | 111 | 116 | 127 | 136 | 122 | 122 | 91.37 |
| Assets | |||||||
| Gross block | 314 | 314 | 312 | 303 | 288 | 261 | 243 |
| Net block | 142 | 146 | 150 | 147 | 139 | 118 | 105 |
| Capital work in progress | 1.59 | 3.09 | 2.00 | 4.09 | 8.38 | 11.94 | 4.19 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 5.70 | 6.03 | 9.80 | 11.95 | 25.56 | 16.60 | 15.00 |
| Sundry debtors | 0.00 | 0.05 | 1.90 | 0.53 | 0.88 | 0.30 | 0.20 |
| Cash & bank balances | 0.13 | 0.14 | 0.14 | 0.09 | 0.10 | 0.71 | 0.17 |
| Loans & advances | 3.79 | 4.04 | 5.61 | 3.50 | 8.95 | 3.81 | 3.49 |
| Total current assets | 9.62 | 10.26 | 17.45 | 16.07 | 35.49 | 21.42 | 18.86 |
| Total current liabilities | 51.78 | 52.57 | 51.66 | 38.98 | 67.90 | 37.60 | 42.43 |
| Net working capital | (42.16) | (42.31) | (34.21) | (22.91) | (32.41) | (16.18) | (23.57) |
| Total assets | 111 | 116 | 127 | 136 | 122 | 122 | 91.37 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.14 | 0.14 | 0.09 | 0.10 | 0.71 | 0.17 | 17.32 |
| Net cash from operating activities | (1.92) | (7.89) | 2.36 | (24.71) | (17.22) | (14.57) | (35.50) |
| Net cash from investing activities | (3.64) | (4.97) | (7.82) | (12.65) | (22.90) | (22.55) | (10.22) |
| Net cash from financing activities | 5.54 | 12.86 | 5.50 | 37.34 | 39.51 | 37.66 | 28.58 |
| Net change in cash | (0.01) | 0.00 | 0.05 | (0.01) | (0.61) | 0.54 | (17.14) |
| Closing cash | 0.13 | 0.14 | 0.14 | 0.09 | 0.10 | 0.71 | 0.17 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -45.2% | -14.1% | -3.3% | -12.7% | +11.2% | +60.7% | - |
| EBITDA growth | +63.7% | -72.6% | +44.9% | +53.5% | -93.6% | +5.4% | - |
| PBT growth | +37.1% | -36.5% | +20.2% | +44.5% | -57.1% | +1.8% | -44.4% |
| Net income growth | +37.4% | -37.2% | +20.2% | +44.5% | -57.1% | +1.9% | - |
| Revenue CAGR (3Y) | -23.1% | -10.2% | -2.1% | +16.0% | +7.7% | +16.7% | +117.2% |
| EBITDA CAGR (3Y) | -29.8% | -23.8% | -20.8% | -5.2% | +51.6% | +25.6% | +28.6% |
| Profitability & leverage | |||||||
| Net income margin | -71.4% | -62.2% | -39.1% | -47.4% | -74.6% | -52.8% | -86.4% |
| Return on capital employed | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Return on net worth | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Debt / equity | 0.00 | 0.00 | 2.83 | 0.78 | 2.23 | 0.00 | 0.00 |
| Long-term debt / equity | 0.00 | 0.00 | 2.34 | 0.54 | 1.74 | 0.00 | 0.00 |
| Interest cover | -59.68 | -27.21 | -30.30 | -13.28 | -13.38 | -27.69 | -25.82 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.08 | 0.14 | 0.16 | 0.18 | 0.22 | 0.21 | 0.14 |
| Inventory turnover | 4.05 | 5.47 | 4.64 | 2.78 | 2.83 | 3.40 | 2.79 |
| Debtors turnover | 949.20 | 44.42 | 41.50 | 73.94 | 101.19 | 214.80 | 21.49 |
| EPS (₹) | (7.85) | (12.49) | (9.15) | (11.45) | (20.65) | (14.45) | (16.04) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | (75.49) | (67.83) | (55.29) | (46.13) | (34.83) | (23.91) | (13.89) |
To see the full year-wise statements and ratios of Krebs Biochemicals and Industries Limited, buy the company report.
Board of directors of Krebs Biochemicals and Industries Limited
Krebs Biochemicals and Industries has 8 current directors and 27 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Avinash Ravi | Director | 13 Aug 2015 | 11 Years 2 Months | Current |
| Ravi Ravindranath Tagore | Director | 12 Oct 1992 | 34 Years 0 Months | Current |
| Pabitrakumar Kalipada Bhattacharyya Also directs: Unichem Laboratories Limited | Director | 10 Aug 2023 | 3 Years 2 Months | Current |
| Manish Kumar Jain | Managing Director | 07 Aug 2025 | 1 Years 2 Months | Current |
| Popatlal Mukanchand Kathariya Also directs: Sam Tax and Finance Services Private Limited | Director | 04 Feb 2025 | 1 Years 9 Months | Current |
| Dipti Chinubhai Shah Also directs: Makers Laboratories Ltd | Director | 04 Feb 2025 | 1 Years 9 Months | Current |
Auditor
Krebs Biochemicals and Industries Limited is audited by Bhavani & Co for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Bhavani & Co | FY 2023 | 012139S |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 72.70%, foreign institutional investors hold 0.50%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 26.80%.
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 72.70% | 72.70% | 72.70% | 72.70% |
| Public | 27.30% | 27.30% | 27.30% | 27.30% |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 26 Aug 2021 | 100477385 | Others | ₹10 Cr | Open | |
| 16 Apr 1994 | 90124704 | State Bank of India | ₹1.35 Cr | Open | |
| 19 Jan 1986 | 90120141 | Industrial Development Bank of India | ₹3 Cr | Open | |
| 25 Aug 2020 | 100367554 | Others | ₹10 Cr | Satisfied | |
| 08 Sep 2011 | 10314172 | Pinky Ventures Private Limited | ₹2 Cr | Satisfied |
To see the full charge records of Krebs Biochemicals and Industries Limited, buy the company report.
Total charge records: 43 View all charges
Deals & funding
Krebs Biochemicals and Industries Limited has 14 deals on record (9 market trades, 2 acquisitions, 2 funding rounds), with disclosed funding of ₹200 Cr; the latest was in November 2024.
Deals on record (5 of 14)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jul 2024 | Market trade | ₹5.63 Cr | Buyer: NK Securities Research Private Limited , N.G.C.S. (P) Ltd. Seller: NK Securities Research Private Limited , N.G.C.S. (P) Ltd. |
| Dec 2021 | Funding round | ₹100 Cr | Investors: Ipca Laboratories Limited |
| Oct 2021 | Funding round | ₹100 Cr | Investors: Ipca Laboratories Limited |
| Aug 2021 | Market trade | ₹3.35 Cr | Seller: Brescon Ventures Private Limited |
| Dec 2020 | Market trade | ₹1.38 Cr | Seller: Brescon Ventures Private Limited |
To see the full deal history of Krebs Biochemicals and Industries Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Krebs Biochemicals and Industries Limited has 114 court cases on record: 56 filed by Krebs Biochemicals and Industries, 58 filed against it. 15 cases are pending and 99 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 71 | 21 | 15 |
| District courts | 41 | 37 | 0 |
| Supreme Court | 2 | 0 | 0 |
Cases on record (5 of 114)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court, TELANGANA | Company petition | Filed against the company by M/S. Trident Chemphar Limited. | Pending |
| High Court of Andhra Pradesh | Company petition | Filed against the company by M/S. Aurobindo Pharma Ltd. | Pending |
| High Court, TELANGANA | Company petition | Filed against the company by M/S. Aurobindo Pharma Ltd. | Pending |
| High Court, ANDHRAPRADESH | Writ petition | Filed by the company against Eastern Power Distribution Company of Andhra Pradesh Ltd., and 1 other | Disposed |
| High Court, ANDHRAPRADESH | Writ petition | Filed by the company against Southern Power Distribution Company of Andhra Pradesh Ltd., and 1 other | Disposed |
To see the full case history of Krebs Biochemicals and Industries Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Krebs Biochemicals and Industries Limited has 32 MSME Form 1 returns on record between 2009 and 2024, listing 3,550 overdue payments to 87 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 87)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Reliability Engineering Industries Private Limited | |||
| an individual supplier | |||
| Production Needs Gases Private Limited | |||
| an individual supplier | |||
| Pragati Polyplast India Private Limited |
To see the full MSME payment records of Krebs Biochemicals and Industries Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Krebs Biochemicals and Industries has 1 associated company. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.
Employees & EPFO
Krebs Biochemicals and Industries Limited has a workforce of 335 employees on its EPFO records as of Apr 02, 2024, across 2 active EPFO establishments.
GST
Krebs Biochemicals and Industries has 3 GST registrations: 2 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 37AAACK8355M1Z0 | Andhra Pradesh | Active | 01 Jul 2017 |
| 36AAACK8355M1Z2 | Telangana | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Krebs Biochemicals and Industries Limited, buy the company report.
Recent activity
Krebs Biochemicals and Industries Limited has 48 board changes on record since 1992: 28 appointments and 20 cessations. The latest: Jitendra Rameshchandra Shah ceased to be CEO on 07 Aug 2025.
151 earlier events are in the company report.
News
Frequently asked questions
Krebs Biochemicals and Industries is an active public limited company based in Anakapalli, Telangana, India. The company works in biotechnology, within the life sciences industry. It was incorporated on 02 December 1991 (35+ years old) and is registered under CIN L24110AP1991PLC103912. Listed on BSE: 524518 and NSE: KREBSBIO.
Krebs Biochemicals and Industries reported revenue of ₹23.73 Cr for FY 2025-26 (down 45.2% YoY) based on standalone financials.
Krebs Biochemicals and Industries has 8 current directors:
- Manish Kumar Jain - Managing Director
- Avinash Ravi - Director
- Ravi Ravindranath Tagore - Director
- Pabitrakumar Kalipada Bhattacharyya - Director
- Popatlal Mukanchand Kathariya - Director
- Dipti Chinubhai Shah - Director
- Satya Prakash Chigurupati - Director
- Sumanth Karlapudi - Director
The latest financial statements of Krebs Biochemicals and Industries on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 26 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Krebs Biochemicals and Industries is 37AAACK8355M1Z0, registered in Andhra Pradesh. The company has 3 GST registrations in all, of which 2 are active and 1 is cancelled or inactive. Other active GSTINs include 36AAACK8355M1Z2 (Telangana).
The CIN (Corporate Identification Number) of Krebs Biochemicals and Industries is L24110AP1991PLC103912. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Krebs Biochemicals and Industries is a listed company as per MCA records. Its shares are listed on both BSE (code: 524518) and NSE (symbol: KREBSBIO).
Krebs Biochemicals and Industries has 114 court cases on record: 56 filed by the company and 58 filed against it. 15 are pending. Most are in the high courts.
Krebs Biochemicals and Industries was incorporated on 02 December 1991, making it 35+ years old. It is registered with the Registrar of Companies, Vijayawada.
Krebs Biochemicals and Industries has 14 deals on record (9 market trades, 2 acquisitions, 2 funding rounds), with disclosed funding of ₹200 Cr; the latest was in November 2024.
Jitendra Rameshchandra Shah ceased to be CEO on 07 Aug 2025. Manish Kumar Jain was appointed as Managing Director on 07 Aug 2025. Satish Khemchand Khivsara ceased to be Director on 01 Apr 2025. Krebs Biochemicals and Industries has 48 board changes on record in total.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
